ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 589

Netosis-Derived Products Might Have Diagnostic Potential for Disease Activity, Atherosclerosis and Analysis of Therapeutic Effectiveness in Rheumatoid Arthritis Patients

Chary Lopez-Pedrera1, Patricia Ruiz-Limon2, Carlos Perez-Sanchez1, Yolanda Jiménez-Gómez1, Maria Carmen Abalos-Aguilera2, Ivan Arias de la Rosa1, Pedro Segui1, Pilar Font-Ugalde1, Maria Ángeles Aguirre Zamorano1, Jerusalem Calvo-Gutierrez1, Rafaela Ortega-Castro1, M. Carmen Castro-Villegas3, Rocio Gonzalez-Conejero4, Constantino Martinez4, Eduardo Collantes-Estévez1, Alejandro Escudero-Contreras2 and Nuria Barbarroja1, 1Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 2Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 3Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, 4Regional Centre for Blood Donation, University of Murcia, Murcia, Spain

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Biomarkers, Cardiovascular disease, NETosis, rheumatoid arthritis (RA) and therapeutic targeting

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Neutrophil extracellular traps (NETs) have recently been implicated in vascular damage and atherothrombosis. Extruded DNA fibers containing multiple proinflammatory and thrombotic molecules induce the activation and recruitment of monocytes and dendritic cells to the vessel wall. Enhanced NETosis occurs in rheumatoid arthritis (RA), which has been shown related to the pathogenesis of this disorder. However, the relevance of this abnormality in the development of atherosclerosis, and the effects of new therapeutic approaches has not been elucidated yet. The aims of this study were: 1) To evaluate the association of netosis-derived products with the development of atherothrombosis in RA. 2) To study the role of biologic therapies in inhibiting NETosis.

Methods: One hundred RA patients and 30 healthy donors were included. Carotid intima media thickness (CIMT) was used as atherosclerosis marker. Inflammatory and prothrombotic molecules and oxidative stress markers were analyzed in plasma. Neutrophils were isolated and spontaneous and induced NETs formation was assessed through fluorescence microscopy. Oxidative stress status (JC1 and DCFH), myeloperoxidase (MPO), and neutrophil elastase (NE) protein expression were measured in neutrophils by flow cytometry. Cell-free DNA plasma levels were analyzed using specific ELISA-base kits. mRNA expression of peptidyl arginine deiminase 4 (PAD4) and various proatherothrombotic molecules were analyzed by RT-PCR.

Results: NETosis was found increased in RA patients, alongside MPO and NE protein expression in neutrophils. Cell free DNA plasma levels were further elevated, and strongly correlated with clinical parameters such as DAS28, CRP and ESR, and autoimmunity state (RF and anti-CCPs positivity). In addition, high levels of cell-free DNA were associated with elevated levels of IL-6, MCP-1, spSelectin and tPA in plasma, as well as with increased NTyr and decreased TAC and NO. At cellular level, cell free DNA plasma levels correlated with increased oxidative status in RA neutrophils (JC1 and DCFH) and mRNA expression of PADI4. Those patients having pathologic CIMT showed increased cell-free DNA plasma levels. Two new cohorts of 60 RA patients, treated either with Infliximab (n=40) or Tocilizumab (n=20) for six months were further evaluated. Both drugs promoted decreased generation of NETs, along with reduction of MPO, NE, PAD4, and the percentage of low density granulocytes, as well as of the proatherothrombotic profile of RA patients.

Conclusion: 1) Elements associated with the extrusion of NETs are significantly enhanced in RA patients. 2) NETosis-derived products, such as cell-free DNA, strongly correlated with clinical parameters, inflammatory and oxidative markers. Thus, NETosis-derived products demonstrated diagnostic potential for disease activity and atherosclerosis, as well as for analysis of therapeutic effectiveness in RA patients. Funded by CTS7940, PI15/01333, PI2013-0191, CP15/00158.


Disclosure: C. Lopez-Pedrera, None; P. Ruiz-Limon, None; C. Perez-Sanchez, None; Y. Jiménez-Gómez, None; M. C. Abalos-Aguilera, None; I. Arias de la Rosa, None; P. Segui, None; P. Font-Ugalde, None; M. Á. Aguirre Zamorano, None; J. Calvo-Gutierrez, None; R. Ortega-Castro, None; M. C. Castro-Villegas, None; R. Gonzalez-Conejero, None; C. Martinez, None; E. Collantes-Estévez, None; A. Escudero-Contreras, None; N. Barbarroja, None.

To cite this abstract in AMA style:

Lopez-Pedrera C, Ruiz-Limon P, Perez-Sanchez C, Jiménez-Gómez Y, Abalos-Aguilera MC, Arias de la Rosa I, Segui P, Font-Ugalde P, Aguirre Zamorano MÁ, Calvo-Gutierrez J, Ortega-Castro R, Castro-Villegas MC, Gonzalez-Conejero R, Martinez C, Collantes-Estévez E, Escudero-Contreras A, Barbarroja N. Netosis-Derived Products Might Have Diagnostic Potential for Disease Activity, Atherosclerosis and Analysis of Therapeutic Effectiveness in Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/netosis-derived-products-might-have-diagnostic-potential-for-disease-activity-atherosclerosis-and-analysis-of-therapeutic-effectiveness-in-rheumatoid-arthritis-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/netosis-derived-products-might-have-diagnostic-potential-for-disease-activity-atherosclerosis-and-analysis-of-therapeutic-effectiveness-in-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology